Fentanyl nasal spray for the treatment of cancer pain

Bibliography

• Coyle N, Adelhardt J, Foley KM, Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990;5:83-93
   PubMedGoogle Scholar
• Quill TE. Doctor, I want to die. Will you help me? JAMA 1993;270:870-3
   PubMed Web of Science ®Google Scholar
• Sawe J, Dahlstrom B, Rane A. Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol 1983;24:537-42
   PubMed Web of Science ®Google Scholar
• Broomhead A, Kerr R, Tester W, Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997;14:63-73
   PubMed Web of Science ®Google Scholar
• Mystakidou K. E-TRANS fentanyl. Curr Opin Investig Drugs 2002;3:463-9
   PubMedGoogle Scholar
• Portenoy RK, Southam MA, Gupta SK, Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993;78:36-43
   PubMed Web of Science ®Google Scholar
• Grond S, Zech D, Lehmann KA, Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997;69:191-8
   PubMed Web of Science ®Google Scholar
• Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 1983;8:422-46
   PubMed Web of Science ®Google Scholar
• Meuldermans WE, Hurkmans RM, Heykants JJ. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 1982;257:4-19
   PubMedGoogle Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne R, Coluzzi P, Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-12
   PubMed Web of Science ®Google Scholar
• Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64
   PubMed Web of Science ®Google Scholar
• Hanks GW, Conno F, Cherny N, Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Katsouda E, Parpa E, Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. J Opioid Manag 2005;1:36-40
   PubMedGoogle Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Tsilika E, Tsiatas M, Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. Int J Nanomed 2007;2:49-54
   PubMed Web of Science ®Google Scholar
• Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today (Barc) 2008;44:41-54
   PubMed Web of Science ®Google Scholar
• Rauck RL, Tark M, Reyes E, Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85
   PubMed Web of Science ®Google Scholar
• Darwish M, Tempero K, Kirby M, Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther 2006;28:715-24
   PubMed Web of Science ®Google Scholar
• Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 1999;90:576-99
   PubMed Web of Science ®Google Scholar
• Lowhagen P, Johansson BB, Nordborg C. The nasal route of cerebrospinal fluid drainage in man. A light-microscope study. Neuropathol Appl Neurobiol 1994;20:543-50
   PubMedGoogle Scholar
• Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002;46:759-70
   PubMed Web of Science ®Google Scholar
• Striebel HW, Kramer J, Luhmann I, Pharmacokinetics of intranasal fentanyl. Schmerz 1993;7:122-5
   PubMedGoogle Scholar
• Christrup LL, Foster D, Popper LD, Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 2008;30:469-81
   PubMed Web of Science ®Google Scholar
• Moksnes K, Fredheim OM, Klepstad P, Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 2008;64:497-502
   PubMed Web of Science ®Google Scholar
• Kaasa S, Moksnes K, Nolte T, Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 2010;6:17-26
   PubMedGoogle Scholar
• Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: a prospective, randomized, double-blind, placebo-controlled study. Clin Ther 2010;32:1427-36
   PubMed Web of Science ®Google Scholar
• Fisher A, Watling M, Smith A, Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther 2010;48:138-45
   PubMed Web of Science ®Google Scholar
• Fisher A, Watling M, Smith A, Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 µg in healthy volunteers. Int J Clin Pharmacol Ther 2010;48:860-7
   PubMed Web of Science ®Google Scholar
• Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2000;20:253-8
   PubMed Web of Science ®Google Scholar
• Kress HG, Oronska A, Kaczmarek Z, Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31:1177-91
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Davies A, A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009;25:2805-15
   PubMed Web of Science ®Google Scholar
• Taylor D, Galan V, Weinstein SM, Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 2010;8:184-90
   PubMedGoogle Scholar
• Portenoy RK, Burton AW, Gabrail N, A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151:617-24
   PubMed Web of Science ®Google Scholar
• Fallon M, Gatti A, Davies A, Efficacy, safety and patient acceptability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multi-center, double-blind, double-dummy, multiple-crossover study. Eur J Cancer Supp 2009;7:15
   Google Scholar
• Davies A, Sitte T, Elsner F, Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 2011;41:358-66
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Raffaeli W, Torres LM, Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag 2010;6:319-28
   PubMedGoogle Scholar